{
  "id": "clinical#screening_cues_1af473e1",
  "content": "agnosis. Individuals with neuroleptic malignant syndrome may have\nleukocytosis, metabolic acidosis, hypoxia, decreased serum iron con-\ncentrations, and elevations in serum muscle enzymes and catechol-\namines. Findings from cerebrospinal fluid analysis and neuroimaging\nstudies are generally normal, whereas electroencephalography shows\ngeneralized slowing. Autopsy findings in fatal cases have been non-\nspecific and variable, depending on complications.\nDevelopment and Course\nEvidence from database studies suggests incidence rates for neuro-\nleptic malignant syndrome of 0.01%–0.02% among individuals treated\nwith antipsychotics. The temporal progression of signs and symp-\ntoms provides important clues to the diagnosis and prognosis of\nneuroleptic malignant syndrome. Alteration in mental status and\nother neurological signs typically precede systemic signs. The onset\nof symptoms varies from hours to days after drug initiation. Some\ncases develop within 24 hours after drug initiation, most within the\nfirst week, and virtually all cases within 30 days. Once the syndrome\nis diagnosed and oral antipsychotic drugs are discontinued, neuro-\nleptic malignant syndrome is self-limited in most cases. The mean\nrecovery time after drug discontinuation is 7–10 days, with most in-\ndividuals recovering within 1 week and nearly all within 30 days.\nThe duration may be prolonged when long-acting antipsychotics are",
  "metadata": {
    "source": "DSM-5",
    "url": "https://psychiatry.org/",
    "condition": "General",
    "risk_band": "low",
    "topics": [
      "screening_cues"
    ],
    "is_clinical": true,
    "is_advice": false
  },
  "index_text": "General — Screening Cues agnosis. Individuals with neuroleptic malignant syndrome may have\nleukocytosis, metabolic acidosis, hypoxia, decreased serum iron con-\ncentrations, and elevations in serum muscle enzymes and catechol-\namines. Findings from cerebrospinal fluid analysis and neuroimaging\nstudies are generally normal, whereas electroencephalography shows\ngeneralized slowing. Autopsy findings in fatal cases have been non-\nspecific and variable, depending on complications.\nDevelopment and Course\nEvidence from database studies suggests incidence rates for neuro-\nleptic malignant syndrome of 0.01%–0.02% among individuals treated\nwith antipsychotics. The temporal progression of signs and symp-\ntoms provides important clues to the diagnosis and prognosis of\nneuroleptic malignant syndrome. Alteration in mental status and\nother neurological signs typically precede systemic signs. The onset\nof symptoms varies from hours to days after drug initiation. Some\ncases develop within 24 hours after drug initiation, most within the\nfirst week, and virtually all cases within 30 days. Once the syndrome\nis diagnosed and oral antipsychotic drugs are discontinued, neuro-\nleptic malignant syndrome is self-limited in most cases. The mean\nrecovery time after drug discontinuation is 7–10 days, with most in-\ndividuals recovering within 1 week and nearly all within 30 days.\nThe duration may be prolonged when long-acting antipsychotics are Agnosis. individuals with neuroleptic malignant syndrome may have\nleukocytosis, metabolic acidosis, hypoxia, decreased serum iron con-\ncentrations, and elevations in serum muscle enzymes and catechol-\namines."
}